ArticleNeuro-oncology advances
Extent of radiological response does not reflect survival in primary central nervous system lymphoma.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Interim FDG-PET improves treatment failure prediction in primary central nervous system lymphoma: An LOC network prospective multicentric study.Neuro-oncology · 2024Trial
- Article
- Primary central nervous system lymphoma-current standards and recent developments.Neuro-oncology practice · 2026Review
- MRI biomarkers of primary CNS lymphoma outcome after MATRix: real world performance.Frontiers in oncology · 2026Article
- MRI patterns of non-enhancing T2-FLAIR hyperintense lesions with dynamic change in primary CNS lymphoma.Frontiers in oncology · 2026Article
- Elevated polyglutamylation and tau phosphorylation levels are associated with cognitive impairment at diagnosis in patients with primary central nervous system lymphoma.Alzheimer's research & therapy · 2025Article
- Automatic Segmentation of Primary Central Nervous System Lymphoma at Clinical Routine Postcontrast T1-weighted MRI.Radiology. Imaging cancer · 2025Article
- Assessing the Effect of Cytoreduction on Solitary, Resectable Lesions in Primary Central Nervous System Lymphoma.Cancers · 2025Article
- Enhancing prognostication and treatment response evaluation in primary CNS lymphoma with 18F-FDG-PET/CT.Neuro-oncology · 2024Article
- Assessing the intracranial metabolic score as a novel prognostic tool in primary CNS lymphoma with end of induction-chemotherapyCancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Outcomes and relapse patterns in primary central nervous system lymphoma: Longitudinal analysis of 559 patients diagnosed from 1983 to 2020.Neuro-oncology · 2024Article
- Radiomic prediction for durable response to high-dose methotrexate-based chemotherapy in primary central nervous system lymphoma.Cancer medicine · 2024Article
- Article
- Diagnostics and treatment delay in primary central nervous system lymphoma: What the neurosurgeon should know.Acta neurochirurgica · 2024Review
- Improved early outcome prediction by MRI-based 3D tumor volume assessment in patients with CNS lymphomas.Neuro-oncology · 2024Article
- Early MRI Predictors of Relapse in Primary Central Nervous System Lymphoma Treated with MATRix Immunochemotherapy.Journal of personalized medicine · 2023Article
- Is there a future for maintenance temozolomide chemotherapy in PCNSL?Neuro-oncology · 2023Article
- Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Review
- Refinement of primary central nervous system lymphoma prognostication and response assessment using 3-dimensional MRI.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn primary central nervous system lymphoma (PCNSL), small enhancing lesions can persist after treatment. It is unknown whether a difference in response category (complete response [CR], complete response unconfirmed [CRu], or partial response [PR]) reflects survival. We aimed to determine the value of a central radiology review on response assessment and whether the extent of response influenced progression-free and/or overall survival.
methodsAll patients in the HOVON 105/ALLG NHL 24 study with at least a baseline MRI and one MRI made for response evaluation available for central review were included. Tumor measurements were done by 2 independent central reviewers, disagreements were adjudicated by a third reviewer. Crude agreement and interobserver agreement (Cohen's kappa) were calculated. Differences in progression-free and overall survival between different categories of response at the end-of-protocol-treatment were assessed by the log-rank test in a landmark survival-analysis.
resultsAgreement between the central reviewers was 61.7% and between local and central response assessment was 63.0%. Cohen's kappa's, which corrects for expected agreement, were 0.44 and 0.46 (moderate), respectively. Progression agreement or not was 93.3% (kappa 0.87) between local and central response assessment. There were no significant differences in progression-free and overall survival between patients with CR, CRu, or PR at the end-of-protocol-treatment, according to both local and central response assessment.
conclusionsReliability of response assessment (CR/CRu/PR) is moderate even by central radiology review and these response categories do not reliably predict survival. Therefore, primary outcome in PCNSL studies should be survival rather than CR or CR/CRu-rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.